Key result
Tenecteplase linked to worse functional outcomes vs standard care in minor stroke patients >80 with occlusion.
Why the study?
Does tenecteplase improve 90-day functional outcomes in older patients (>80 years) with minor ischemic stroke compared to standard of care?
RCT
randomized
Yes
Does tenecteplase improve 90-day functional outcomes in older patients (>80 years) with minor ischemic stroke compared to standard of care?
In older patients (>80 years) with minor ischemic stroke, IV thrombolysis with tenecteplase is associated with worse 90-day functional outcomes and more adverse events compared to standard of care.
Answers are grounded in this paper and cite their sources.
May warrant withholding IV thrombolysis in patients >80 with minor stroke; challenges routine extension to this population.
BACKGROUND AND OBJECTIVES: There are few high-quality data on thrombolysis outcomes in the oldest patients, especially for minor stroke. We examined safety and efficacy outcomes of thrombolysis in patients older than 80 years, compared with those ≤80 years, in the Tenecteplase Versus Standard of care for Minor Ischaemic Stroke With Proven Occlusion (TEMPO-2) trial. METHODS: In this post hoc analysis of the TEMPO-2 randomized controlled trial, we compared outcomes and adverse events in patients with minor stroke and symptomatic intracranial occlusion or focal perfusion lesion within 12 hours of symptom onset, assigned to tenecteplase vs nonthrombolytic standard of care, in those >80 years and ≤80 years. The primary outcome was responder analysis of the 90-day modified Rankin Scale (responder was mRS = 0-1 if premorbid mRS = 0-1, 0-2 if premorbid mRS = 2). Secondary outcomes included neurologic recovery according to the NIH Stroke Scale (NIHSS) at 5 days/discharge, vessel recanalization, Lawton Instrumental Activities of Daily Living Scale, EuroQol-5 Dimension (EQ-5D), and adverse events. We used mixed-effects Poisson, ordinal logistic, and quantile regression as appropriate, adjusted for sex, baseline NIHSS, and treatment assignment as fixed-effects and enrolling site as random effects. DISCUSSION: Older patients (>80 years) with minor stroke and visible occlusion or perfusion lesion assigned to tenecteplase were more likely to achieve recanalization of occlusions and short-term neurologic recovery, as were younger patients, but they experienced worse 90-day outcomes with more frequent hemorrhagic and stroke progression/recurrence-related SAEs. Overall, these results, while post hoc, do not support thrombolysis for minor strokes in older patients. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov: NCT02398656. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in patients >80 years with minor stroke and visible occlusion or perfusion lesion, IV thrombolysis with tenecteplase is associated with worse functional outcomes at 90 days compared with nonthrombolytic standard of care therapies.
No takes yet. Share an insight, caveat, or question.
Ganesh et al. (2026) conducted an RCT in minor ischemic stroke. Tenecteplase vs. Nonthrombolytic standard of care was evaluated on Responder analysis of the 90-day modified Rankin Scale (responder was mRS = 0-1 if premorbid mRS = 0-1, 0-2 if premorbid mRS = 2) (p=0.026). Tenecteplase was associated with worse 90-day functional outcomes compared with standard of care in patients >80 years with minor stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: